Impact of guideline-concordant antibiotics and macrolide/β-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study  by Asadi, L. et al.
Impact of guideline-concordant antibiotics and macrolide/b-lactam
combinations in 3203 patients hospitalized with pneumonia: prospective
cohort study
L. Asadi1, D. T. Eurich2, J. M. Gamble2, J. K. Minhas-Sandhu2, T. J. Marrie3 and S. R. Majumdar1,2
1) The Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, 2) Department of Public Health Sciences, School of Public Health,
University of Alberta, Edmonton, AB and 3) Department of Medicine, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada
Abstract
For patients hospitalized with pneumonia, guidelines provide empirical antibiotic recommendations and some studies suggest that mac-
rolide/b-lactam combinations are preferable. We hypothesized that guideline-concordant regimens, particularly macrolide/b-lactams,
would reduce mortality and ICU admissions. All patients hospitalized with pneumonia in Edmonton, Alberta, Canada, were managed
according to a clinical pathway and enrolled in a population-based registry. Clinical data, Pneumonia Severity Index and treatments were
collected. Guideline-concordant regimens were macrolides/b-lactams or respiratory ﬂuoroquinolone monotherapy. The main outcome
was in-hospital mortality. The study included 3203 patients and most had severe pneumonia (63% PSI Class IV-V). Three hundred and
twenty-one (10.0%) patients died, 306 (9.6%) were admitted to the ICU and 570 (17.8%) achieved the composite of death or ICU
admission. Most (n = 2506) patients received guideline-concordant antibiotics. Receipt of guideline-concordant antibiotics was not asso-
ciated with a reduction in mortality alone (231 (9.2%) vs. 90 (12.9%); adjusted odds ratio (aOR), 0.82; 95% CI, 0.61–1.09; p 0.16), but
was associated with decreased death or ICU admission (14.7% vs. 29.0%; aOR, 0.44; 95% CI, 0.36–0.54; p <0.0001). Within guideline-
concordant subgroups, there was no difference in mortality between macrolide/b-lactams and respiratory ﬂuoroquinolone monotherapy
(22 (8.3%) vs. 209 (9.3%); aOR, 1.09; 95% CI, 0.66–1.81; p 0.73) but macrolide/b-lactams were associated with increased odds of death
or ICU admission (17.4% vs. 14.4%; aOR, 1.58; 95% CI, 1.09–2.27; p 0.01). In conclusion, guideline-concordant antibiotics were not
associated with decreased mortality for patients hospitalized with pneumonia, but were associated with a decrease in the composite
endpoint of death or ICU admission. Our ﬁndings do not support any clinical advantage of macrolide/b-lactam compared with respira-
tory ﬂuoroquinolone monotherapy.
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Introduction
Community-acquired pneumonia (CAP), combined with
inﬂuenza, is the eighth leading cause of death in Canada
and the United States [1,2]. For patients hospitalized with
pneumonia, 30-day mortality rates are between 1 and 23%
[3], with annual expenditures estimated at $8 to $10 billion
[4]. Given the high burden of morbidity and mortality asso-
ciated with pneumonia and the limitations of available diag-
nostic studies to identify pathogens [5], the Infectious
Diseases Society of America/American Thoracic Society and
other expert organizations suggest empirical treatment [4].
Guideline recommendations are based on the likely aetio-
logical agents, expected susceptibilities and expert opinion,
but have rarely been subjected to randomized controlled
trials.
Several observational studies have reported that use of
guideline-concordant antibiotics reduces morbidity and mor-
tality [6–13]. Among guideline-concordant options, several
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observational studies have suggested improved outcomes
with macrolide-based regimens, perhaps because of these
agents’ putative immunomodulatory properties [14–23]. The
evidence base for this possibility is even more limited than
for guideline concordance in general, particularly for direct
comparisons of macrolide/b-lactam regimens with respiratory
ﬂuoroquinolones [19–23].
Therefore, we assessed the impact of guideline-concor-
dant antibiotic regimens on mortality and morbidity in
patients hospitalized with pneumonia. We hypothesized that
guideline-concordant regimens in general, and macrolide/
b-lactam regimens in particular, would be associated with
decreased in-hospital mortality or the composite endpoint of
death or intensive care unit (ICU) admission when compared
with other treatment options.
Methods
Subjects and setting
Details of the study cohort were previously published [23–
25]. This study looked at the subgroup of patients admitted
to hospital (excluding those directly admitted to the ICU). In
summary, data were collected from 2000 to 2002 using a
previously validated clinical pathway for managing CAP [26].
This was implemented in six local hospitals (two tertiary care
hospitals, two hospitals providing secondary and some ter-
tiary care, and two community hospitals) in Edmonton,
Alberta, Canada.
CAP was deﬁned as two or more symptoms or signs
(cough, pleuritic chest pain, shortness of breath, tempera-
ture >38C, and crackles or bronchial breathing on auscul-
tation) plus radiographic evidence of pneumonia as
interpreted by the treating physician (prior to conﬁrmation
by a radiologist). The following conditions resulted in exclu-
sion from the pathway: tuberculosis, cystic ﬁbrosis, immu-
nocompromised state, human immunodeﬁciency virus,
pregnancy, breast-feeding, hospitalization for any reason in
the previous 10–14 days and frank aspiration pneumonia.
After initial triage and assessment in the emergency depart-
ment, all patients admitted to hospital were treated in a
standardized manner according to the clinical pathway, con-
sisting of admission criteria and preprinted orders covering
routine aspects of care. This cohort was part of the evalua-
tion of a population-based quality improvement interven-
tion. As such, the requirement for informed patient
consent was waived and our study was approved by our
Health Research Ethics Board (University of Alberta,
approval #4999).
Data collection
Trained research nurses collected sociodemographic vari-
ables, clinical characteristics, laboratory tests and chest
radiograph data (based on ofﬁcial interpretation by a board-
certiﬁed radiologist). Pre-morbid functional status was based
on patient or proxy self-report and categorized as walking
(independent) vs. any impairment (i.e. walking with assis-
tance, walking with a prosthesis, wheel chair or bed-bound
status); hereafter we refer to the latter as impaired pre-mor-
bid functional status. Microbiological specimens were col-
lected at the discretion of the attending physician although
blood and sputum cultures were recommended for all
patients. Pneumonia Severity Index (PSI) was calculated at
point of care. [25,27].
Antibiotic regimens
The antibiotics recommended in the clinical pathway were
cefotaxime/azithromycin or levoﬂoxacin monotherapy. This
was based on the 2000 IDSA CAP guidelines [28] and closely
corresponds with 2003 and 2007 guidelines [4,29]. For the
purposes of our study, guideline-concordant antibiotics were
respiratory ﬂuoroquinolone monotherapy (not ciproﬂoxacin)
or macrolide/b-lactam regimens. Guideline-concordant mac-
rolides were azithromycin, clarithromycin or erythromycin.
Guideline-concordant b-lactams were second or third-gener-
ation cephalosporins or amoxicillin-clavulunate. Any other
regimen was ‘guideline discordant’. We considered our ana-
lytical framework to reﬂect the ‘intention-to-treat’ approach,
that is, antibiotic regimens were selected without knowledge
of microbiology or clinical response. We had limited data
regarding escalation of therapy, and only recorded whether
new antibiotics were started or substituted after 24 h of
hospitalization.
Outcomes
Our primary outcome measure was in-hospital mortality. In
addition, we examined ICU admissions and the composite
endpoint of in-hospital mortality or ICU admission.
Analyses
Baseline characteristics of patients receiving guideline-con-
cordant vs. discordant antibiotics were compared using para-
metric or non-parametric tests, as appropriate. Multivariable
logistic regression was used to determine the independent
association between receipt of guideline-concordant antibiot-
ics and outcomes. We forced use of guideline-concordant
antibiotics (dichotomous variable representing the indepen-
dent exposure of interest), the PSI (continuous summary
measure of pneumonia severity calculated using 20 variables:
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age, sex, nursing home status, ﬁve co-morbidities, ﬁve physi-
cal signs and seven laboratory ﬁndings), pre-morbid func-
tional status and board-certiﬁed radiologist conﬁrmation of
pneumonia by chest radiograph into all models. Because the
PSI already includes age, sex and nursing home residence, we
did not further adjust for them. We then considered other
variables based on clinical importance, univariate p-values
<0.1 or when a variable confounded (i.e. a > 10% change in
beta-coefﬁcient) the association between antibiotics and out-
comes, irrespective of statistical signiﬁcance. The ﬁnal models
included the forced variables, any variable with an adjusted
p-value <0.05, or any confounding variable. We tested all
ﬁrst-order interaction terms, but none achieved statistical
signiﬁcance and none were included in the models. We con-
sidered a p-value of <0.05 to represent statistical signiﬁcance
(Appendices S1–S5).
We then restricted analyses to patients who had received
guideline-concordant antibiotics. We compared macrolide/
b-lactams with ﬂuoroquinolone monotherapy and undertook
identical analyses to those already described. We also com-
pared macrolide/b-lactams with respiratory ﬂuoroquinolone/
b-lactams.
We conducted several additional analyses. First, we
undertook all above-mentioned analyses but considered the
composite endpoint of in-hospital mortality or ICU admis-
sion as the outcome of interest. Second, we looked at the
outcome of ICU admission alone. Third, using standard
methods [30,31], we conducted a propensity (to receive
guideline-concordant antibiotics or macrolide/b-lactams)
score adjusted analysis of outcomes rather than the tradi-
tional multivariable logistic regression models used for our
main analyses. Variables included in the propensity score
were all variables presented in Table 1 (except S. pneumo-
niae infection) as well as receipt of antibiotics prior to
admission, site of care, and a term for age-squared that
improved model ﬁt as assessed by the c-statistic [30,31].
Fourth, we re-ran the main analyses after excluding patients
with chest radiographs interpreted as ‘normal’ by a radiolo-
gist, as some experts still contend that one cannot have
pneumonia without radiographic abnormalities on plain ﬁlms
[32,33]. Fifth, we re-ran analyses after excluding 1164
patients considered to be in the ‘HCAP proxy’ group
because of nursing home residence, end-stage chronic kid-
ney disease, or antibiotic treatment before presentation.
Finally, we examined outcomes only in patients with
S. pneumoniae pneumonia as it has a high case-fatality rate
and remains the most common cause of pneumonia. These
analyses were replicated in the guideline-concordant sub-
group. All analyses were conducted using SAS version 9.2
(SAS Institute Inc., Cary, NC, USA.)
Results
Patient characteristics
Overall, 6875 adults were triaged and treated according to a
validated clinical pathway for pneumonia. A total of 3203
patients were admitted to hospital. Mean age was 69 (SD18)
years, 52.4% were female, and 62.7% had severe (PSI Class
IV-V) pneumonia (Table 1). Most (68%) patients had blood
cultures drawn and 41% had sputum cultures collected.
Blood cultures were positive in 147 (7%) cases and sputum
cultures were positive in 363 (33%) cases. Streptococcus pneu-
moniae was the most common pathogen identiﬁed (Table 2).
Overall, 321 (10.0%) patients died in hospital, 306 (9.6%)
were admitted to the ICU and 570 (17.8%) achieved the
composite endpoint. Characteristics of patients according to
death or ICU admission status are presented in Table 3.
Guideline-concordant vs. discordant antibiotic use and out-
comes
Most (n = 2506, 78.2%) patients received guideline-concor-
dant antibiotics (Appendix S1), primarily levoﬂoxacin mono-
therapy (n = 2241, 70.0%). Although patients who received
guideline-concordant antibiotics were older, they were less
likely to have impaired pre-morbid functional status and no
more likely to be from a nursing home (Table 1). Only 152
TABLE 1. Characteristics of 3203 patients hospitalized with
pneumonia according to the use of guideline-concordant
antibiotics
Characteristics
Guideline-
concordant
antibiotics
n = 2506
No. (%)
Guideline-
discordant
antibiotics
n = 697
No. (%) p value
Age in years, mean (SD) 70 ± 18 66 ± 19 <0.001
Age >65 1723 (68.8) 408 (58.5) <0.001
In-hospital mortality 231 (9.2) 90 (12.9) 0.004
Composite of in-hospital
mortality and ICU admission
368 (14.7) 202 (29.0) <0.0001
Female 1295 (51.7) 386 (55.4) 0.08
Nursing home resident 472 (18.8) 144 (20.7) 0.28
Current smoker 604 (24.1) 182 (26.1) 0.28
Impaired pre-morbid
functional status
254 (10.1) 94 (13.5) 0.01
Co-morbidities
Cancer 347 (13.8) 120 (17.2) 0.03
COPD 802 (32.0) 196 (28.1) 0.05
Coronary artery disease 709 (28.3) 154 (22.1) 0.001
Diabetes mellitus 139 (5.5) 33 (4.7) 0.40
Chronic kidney disease 343 (13.7) 116 (16.6) 0.049
Pneumonia severity index
score, mean (SD)
102 ± 35 105 ± 39 0.047
Class I 32 (1.3) 20 (2.9) <0.001
Class II 419 (16.7) 124 (17.8)
Class III 495 (19.8) 103 (14.8)
Class IV 1030 (41.1) 255 (36.6)
Class V 530 (21.1) 195 (28.0)
Chest radiograph conﬁrmed pneumonia 1759 (70.2) 535 (76.8) <0.001
S. pneumoniae infection 155 (6.2) 54 (7.7) 0.14
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(4.7%) patients had their antibiotic treatments switched or
added to after the ﬁrst 24 h of hospitalization, although
patients receiving discordant antibiotics were four times
more likely than those receiving guideline-concordant antibi-
otics to have their treatment escalated (11% vs. 3%,
p <0.001).
Patients receiving guideline-concordant therapy were less
likely to die in hospital: 231 (9.2%) vs. 90 (12.9%), p 0.004,
but this association was not statistically signiﬁcant in adjusted
analyses (aOR, 0.82; 95% CI, 0.61–1.09; p 0.16) (Appendix
S2). The propensity score (c-statistic for model = 0.76)
adjusted OR for mortality with concordant vs. discordant
antibiotics was of almost identical magnitude and not statisti-
cally signiﬁcant (0.84; 95% CI, 0.63–1.12; p 0.23). However,
use of guideline-concordant antibiotics resulted in a decrease
in the composite endpoint of in-hospital mortality or ICU
admission: 368 (14.7%) vs. 202 (29.0%), which remained
strong and statistically signiﬁcant on adjusted analysis (aOR,
0.44; 95% CI, 0.36–0.54; p <0.0001) (Appendix S3). There
was also a decrease in ICU admissions (aOR, 0.33; 95% CI,
0.26–0.43; p <0.0001). In terms of the remainder of our sen-
sitivity analyses, the main results of our analyses with respect
to in-hospital mortality were essentially unaltered (Fig. 1).
Macrolide/b-lactam vs. respiratory ﬂuoroquinolone mono-
therapy
Within the guideline-concordant subgroup of 2506 patients,
there were 2241 (89.4%) patients who received levoﬂoxacin
monotherapy and 265 (10.6%) who received a macrolide/b-
lactam. Macrolide/b-lactam recipients were younger, less
TABLE 2. Bacteria isolated in 3203 patients hospitalized
with pneumonia
Sputum
No. (%)
ETTa/lavage
No. (%)
Blood culture
No. (%)
Total 363/1108 93/218 172/2205
Streptococcus pneumoniae 114 (10.3) 22 (10.1) 91 (4.1)
Haemophilus sp.b 77 (6.9) 22 (10.1) 3 (0.1)
Staphylococcus aureus 50 (4.5) 24 (11.0) 30 (1.4)
Moraxella catarrhalis 29 (2.6) 4 (1.8) 0 (0.0)
Streptococcus sp.c 30 (2.7) 16 (7.3) 11 (0.5)
Pseudomonas aeruginosa 32 (2.9) 3 (1.4) 3 (0.1)
Escherichia coli 6 (0.5) 0 (0.0) 25 (1.1)
Klebsiella sp.d 12 (1.1) 0 (0.0) 5 (0.2)
Othere 13 (1.2) 2 (0.9) 4 (0.2)
aEndotracheal tube cultures.
bHaemophilus sp. includes: H. inﬂuenzae and H. parainﬂuenzae.
cStreptococcus sp. includes: S. agalactiae, S. pyogenes, S. viridans and S. anginosus.
dKlebsiella sp. includes: K. pneumoniae, K. oxytoca and K. ozaenae.
eIncludes but not limited to: Alcaligenes xylosoxidans, Stenotrophomonas maltophilia
and Proteus mirabilis.
TABLE 3. Characteristics of 3203 patients hospitalized with
pneumonia according in-hospital mortality
Characteristics
Death
n = 321
No. (%)
No death
n = 2882
No. (%)
p value
Age in years, mean (SD) 79 ± 13 68 ± 18 <0.001
Age >65 288 (89.7) 1843 (63.9) <0.001
Female 182 (56.7) 1499 (52.0) 0.11
Guideline-concordant antibiotic
regimen
231 (72.0) 2275 (78.9) 0.004
Macrolide/b-lactam regimen 22 (6.9) 243 (8.4)
Nursing home resident 115 (35.8) 501 (17.4) <0.001
Impaired pre-morbid functional
status
85 (26.5) 263 (9.1) <0.001
Current smoker 46 (14.3) 740 (25.7) <0.001
Co-morbidities
Cancer 79 (24.6) 388 (13.5) <0.001
COPD 106 (33.0) 892 (31.0) 0.44
Coronary artery disease 112 (34.9) 751 (26.2) <0.001
Diabetes mellitus 22 (6.9) 150 (5.2) 0.21
Chronic kidney disease 82 (25.5) 377 (13.1) <0.001
Pneumonia severity index score,
mean (SD)
137 ± 32 99 ± 34 <0.001
Class I 0 (0) 52 (1.8) <0.001
Class II 5 (1.6) 538 (18.7)
Class III 17 (5.3) 581 (20.2)
Class IV 111 (34.6) 1174 (40.7)
Class V 188 (58.6) 537 (18.6)
Chest radiograph conﬁrmed
pneumonia
252 (78.5) 2042 (70.9) 0.004
S. pneumoniae infection 16 (5.0) 193 (6.7) 0.24
0.84
0.7
0.7
0.82
0.82
0 0.5 1 1.5 2 2.5 3
Excludes "HCAP proxy" patients4
107/1608 (6.7%) v 46/431 (10.7%)
Confirmed S. pneumoniae infection
9/155 (5.8%) v 7/54 (13.0%)  
Adjusted 
OR1: Reduced risk Increased risk
Excludes normal chest radiographs3
182/1759 (10.1%) v 70/535 (13.1%) 
Propensity score analysis2
231/2506 (9.2%) v 90/697 (12.9%)*
Main analysis 
231/2506 (9.2%) v 90/697 (12.9%)
FIG. 1. Sensitivity analyses with respect to in-hospital mortality
comparing guideline-concordant antibiotics with guideline-discordant
antibiotics. *Crude data always comparing guideline-concordant anti-
biotics vs. guideline-discordant antibiotics. 1Adjusted OR: all the ORs
reported are adjusted odds ratios from multivariable analyses. 2Pro-
pensity Score Analysis: rather than conventional adjustment, analyses
adjusted for the predicted probability [propensity] of a patient to be
prescribed guideline-concordant antibiotics based on admission char-
acteristics. Please refer to Methods for further details regarding deri-
vation and use of propensity score. 3Excludes normal chest
radiographs: analysis was run after excluding patients with chest
radiographs interpreted as abnormal by the admitting physician but
subsequently read as ‘normal’ by a board-certiﬁed radiologist.
4Excludes ‘HCAP proxy’ patients: analysis was run after excluding
patients considered to be in the ‘HCAP proxy’ group because of
nursing home residence, end-stage chronic kidney disease or antibi-
otic treatment before presentation.
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likely to reside in a nursing home and had less severe
pneumonia (Table 4). However, macrolide/b-lactam use was
not independently associated with reduced in-hospital mor-
tality (22 (8.3%) vs. 209 (9.3%); aOR, 1.09; 95% CI, 0.66–
1.81; p 0.73) (Appendix S4). The propensity score (c-statis-
tic for model = 0.81) adjusted OR mortality with macro-
lide/b-lactam antibiotics was 1.31 (95% CI, 0.78–2.20;
p 0.32). This combination was, however, associated with an
increase in both the composite outcome of death or ICU
admission (46 of 265 (17.4%) vs. 322 of 2241 (14.4%);
aOR, 1.58; 95% CI, 1.09–2.27; p 0.01)) and in ICU admis-
sion alone (aOR, 1.79; 95% CI, 1.16–2.78; p 0.009) (Appen-
dix S5). In terms of the remainder of our sensitivity
analyses, the main results of our analyses with respect to
in-hospital all-cause mortality were essentially unaltered
(Fig. 2). When we compared the 265 patients receiving
macrolide/b-lactam antibiotics with those receiving ﬂuoroqu-
inolone/b-lactams, there was no difference in in-hospital
mortality (aOR, 0.75; 95% CI, 0.395–1.42; p 0.38) or in the
composite outcome (aOR, 0.74; 95% CI, 0.46–1.19; p 0.21).
Discussion
In a population-based cohort of over 3000 patients hospital-
ized with pneumonia and managed according to a validated
clinical pathway, we found that high rates (78.2%) of guide-
line-concordant antibiotic treatment could be achieved.
Guideline-concordant antibiotic use was not associated with
in-hospital mortality beneﬁt but was associated with a signiﬁ-
cant 56% adjusted reduction in the composite endpoint of
in-hospital death or ICU admission. Among the guideline-
concordant regimens, contrary to our hypotheses, we found
macrolide/b-lactam regimens were not associated with
decreases in in-hospital mortality or the composite outcome
of death or ICU admission.
At least three retrospective cohort studies involving
about 3000 patients [8,9,11] and four administrative data-
base studies with about 100 000 patients [6,7,12,13] have
reported decreased mortality with guideline-concordant
antibiotics. Given the limitations of randomized trials in this
area, some have highlighted the necessity of relying on
observational data [34]. Indeed, the mounting observational
data (including our ﬁndings related to ICU admission) sup-
ported by studies providing insight into the microbiological
aetiologies of CAP [10] make more widespread adoption of
TABLE 4. Characteristics of the 2506 patients hospitalized
with CAP who received guideline-concordant antibiotics
stratiﬁed by antibiotic treatment
Characteristics
Macrolide/b-
lactam
n = 265
No. (%)
Respiratory
ﬂuoroquinolone
monotherapy
n = 2241
No. (%) p value
Age in years, mean (SD) 64 ± 19 71 ± 17 <0.001
Age >65 146 (55.1) 1577 (69.5) <0.001
Female 137 (51.7) 1158 (51.7) 0.99
In-hospital mortality 22 (8.3) 209 (9.3) 0.59
Composite of in-hospital mortality
and ICU admission
46 (17.4) 322 (14.4) 0.19
Nursing home resident 31 (11.7) 441 (19.7) 0.002
Current smoker 79 (29.8) 525 (23.4) 0.02
Impaired pre-morbid functional
status
21 (7.9) 233 (10.4) 0.21
Co-morbidities
Cancer 33 (12.5) 314 (14.0) 0.49
COPD 85 (32.1) 717 (32.0) 0.98
Coronary artery disease 53 (20.0) 656 (29.3) 0.002
Diabetes mellitus 13 (4.9) 126 (5.6) 0.63
Chronic kidney disease 31 (11.7) 312 (13.9) 0.32
Pneumonia severity index score,
mean (SD)
93 ± 38 103 ± 34 <0.001
Class I 4 (1.5) 28 (1.2) <0.001
Class II 74 (27.9) 345 (15.4)
Class III 54 (20.4) 441 (19.7)
Class IV 87 (32.8) 943 (42.1)
Class V 46 (17.4) 484 (21.6)
Chest radiograph conﬁrmed pneumonia 185 (69.8) 1574 (70.2) 0.89
S. pneumoniae infection 22 (8.3) 133 (5.9) 0.13
1.31
0.56
1.63
0.94
1.09
0 2 4 6 8 1
Excludes "HCAP proxy" patients4
14/172 v (8.1%) v 93/1436 (6.5%)
Confirmed S. pneumoniae infection
1/22 (4.6%) v 8/133 (6.0%)  
Adjusted 
OR1: Increased riskReduced risk
Excludes normal chest radiographs3
20/185 (10.8%) v 162/1574 (10.3%) 
Propensity score analysis2
22/265 (8.3%) v 209/2241 (9.3%)* 
Main analysis
22/265 (8.3%) v 209/2241 (9.3%) 
FIG. 2. Sensitivity analyses with respect to in-hospital mortality
comparing macrolide/b-lactams with respiratory ﬂuoroquinolone
monotherapy. *Crude data always comparing guideline macrolide/
b-lactams vs. respiratory ﬂuoroquinolone monotherapy. 1Adjusted
OR: all the ORs reported are adjusted odds ratios from multivari-
able analyses. 2Propensity score analysis: rather than conventional
adjustment, analyses adjusted for the predicted probability [propen-
sity] of a patient to be prescribed macrolide/b-lactam combination
therapy based on admission characteristics. Please refer to Methods
for further details regarding derivation and use of propensity score.
3Excludes normal chest radiographs: analysis was run after excluding
patients with chest radiographs interpreted as abnormal by the
admitting physician but subsequently read as ‘normal’ by a board-cer-
tiﬁed radiologist. 4Excludes ‘HCAP proxy’ patients: analysis was run
after excluding patients considered to be in the ‘HCAP proxy’ group
because of nursing home residence, end-stage chronic kidney disease
or antibiotics treatment before presentation.
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guideline-concordant antibiotic regimens a prudent clinical
decision [35].
A more controversial question is whether macrolide/b-
lactam combinations are superior to respiratory ﬂuoroqui-
nolone monotherapy and we found that within our guide-
line-concordant subgroup, macrolide/b-lactams were inferior
(or at best equivalent) to respiratory ﬂuoroquinolone mono-
therapy. While others have found macrolide use is associ-
ated with reduced morbidity and mortality [14–22,36,37],
many of these studies compared macrolide/b-lactam regi-
mens with b-lactams alone or looked at combination ther-
apy vs. monotherapy [36,37]. Indeed, there have been six
observational studies and a meta-analysis of randomized tri-
als that have attempted the clinically germane comparisons
of empirical macrolide/b-lactam regimens with respiratory
ﬂuoroquinolone monotherapy as we did [19–22,38–40].
Four of these observational studies suggest the mortality
beneﬁts of macrolide-based regimens are restricted to bac-
teraemic or critically ill patients [19–22]. Our ﬁndings tend
to refute these four studies but are consistent with two
studies conducted among a general population of ward
patients that reported that ﬂuoroquinolone monotherapy
was associated with reductions in mortality [38] and
decreased lengths of stay [39] when compared with macro-
lide/b-lactam regimens. Our ﬁndings are also consistent with
a recent meta-analysis of randomized trials that reported
increased ‘clinical success’ (OR, 1.39; 95% CI, 1.02–1.90) but
no differences in mortality with ﬂuoroquinolone compared
with macrolide/b-lactams [40].
Strengths and Limitations
Despite the strengths of this study, we acknowledge several
limitations. First, it was not a randomized trial. The choice of
discordant antibiotics was up to the treating physician and
we do not know why they chose the regimens they did. Sim-
ilarly, choice of macrolide/b-lactam was left to individual phy-
sicians, and it was clear they were prescribed to younger
patients with less severe pneumonia. Second, we had incom-
plete microbiological data and did not speciﬁcally look for
atypical organisms. Third, some might be concerned about
the vintage of our data and its generalizability to current
practice patterns. For example, erythromycin (though hardly
used) was considered a concordant antibiotic choice and
newer agents such as moxiﬂoxacin were rarely used. Given
that our study is population based, that outcomes have not
changed much over the last decade and that the guidelines
available today are broadly similar to the ones we used, we
do not think this is a major limitation. Another example is
the fact that we included nursing home patients who are
now considered to have healthcare-associated pneumonia
[41]. The entity of healthcare-associated pneumonia and its
diagnostic criteria and treatment have been strongly con-
tested [42]. We adjusted for nursing home status and
excluded those who were recently hospitalized.
Conclusion
In a prospective cohort study of over 3000 patients hospital-
ized with pneumonia, we found that guideline-concordant
antibiotic use with either macrolide/b-lactam regimens or a
respiratory ﬂuoroquinolone did not alter in-hospital mortal-
ity but was associated with a reduction in the endpoint of
death or ICU admission. Contrary to our hypotheses, we
found no advantage of macrolide/b-lactams over respiratory
ﬂuoroquinolone monotherapy. Including our work, the total
weight of evidence suggests that empirical guideline-concor-
dant treatment with atypical pathogen coverage is more
important than the actual agents used. However, given the
conﬂicting data and potential for additional reductions in
mortality, morbidity and cost, we believe sufﬁcient clinical
equipoise exists for randomized controlled trials to be
undertaken to determine the optimal regimen for patients
hospitalized with pneumonia.
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